- Policy
- The legislation of cold chain improvement plan is announced
- by Lee, Hye-Kyung Jan 30, 2023 05:55am
- Following biological agents such as insulin, the cold chain regulations for refrigerated and frozen medicines such as eye drops will be eased. The Ministry of Food and Drug Safety announced today (26th) a revision to the "Prime Ministerial Decree on Safety of Drugs," which includes reasonable improvement in temperature management methods t
- Company
- HKinno.N exports new drug K-CAB technology to Brazil
- by Chon, Seung-Hyun Jan 30, 2023 05:54am
- HKinno.N announced on the 26th that it has signed a technology export contract with Brazilian pharmaceutical company Eurofarma for the new drug K-CAB for gastroesophageal reflux disease. HKinno.N will transfer the manufacturing technology of K-CAB to Eurofarma, and Eurofarma will develop and sell K-CAB in Brazil. Along with the down payment,
- Company
- SK Bioscience proposes building a vaccine hub in Middle East
- by Jan 30, 2023 05:54am
- SK Bioscience announced on the 27th that the company’s CEO, Jae-Yong Ahn, participated in the ‘2023 Riyadh Global Medical Biotechnology Summit’ that was held in Riyadh, the capital of the Kingdom of Saudi Arabia, and proposed a partnership for vaccine supply on the 25th (local time). The Riyadh Summit, which celebrated its second ev
- Company
- Practice manual issued for COVID-19 treatments in Korea
- by Jan 30, 2023 05:54am
- Doctors have issued a ‘Practice Manual’ to provide an understanding of how to use the COVID-19 treatment in one glance. The manual was prepared to directly address difficulties HCPs experienced prescribing COVID-19 treatments in the field due to a large number of contraindicated drugs. The Korean Society for Antimicrobial Therapy (KSAT) rec
- Policy
- Price of Dutasteride has fallen to the 200 won range
- by Lee, Tak-Sun Jan 30, 2023 05:54am
- The upper limit of Dutasteride products used for prostatic hypertrophy and hair loss has fallen to around 200 won. The effect of cascading drug prices is large, and it is expected to affect the hair loss treatment market. According to industries on the 27th, TELCON RF PHARMACEUTICAL's Durid 0.5mg will be listed at the upper limit of 267 won o
- Company
- HK inno.N introduces biosimilar for Prolia & Xgeva
- by Lee, Seok-Jun Jan 27, 2023 05:51am
- HK inno.N announced on the 25th that it has signed an exclusive license contract for Denosumab biosimilar, a treatment for preventing osteoporosis and cancer-related skeletal complications in Mabxience, Spain. HK inno.N will receive an exclusive supply of two Denosumab biosimilars from Mabxience to apply for and sell domestic licenses. Denosu
- Policy
- Negotiating Erleada's price with the NHIS
- by Lee, Tak-Sun Jan 27, 2023 05:51am
- It has been confirmed that Erleada, Janssen Korea's prostate cancer treatment, is negotiating drug prices with the NHIS. This drug was conditionally passed at the deliberation of the HIRA Drug Benefit Evaluation Committee in December last year. According to industries on the 25th, it is negotiating Erleada's price with the NHIS. Erleada was p
- Company
- Flu activity rises...revives Tamiflu market
- by Jan 27, 2023 05:51am
- The influenza treatment market, which had virtually disappeared after the spread of COVID-19, has revived for the first time in 3 years. With the number of flu patients surging due to the flu epidemic, the number of quarterly prescriptions soared from less than KRW 100 million to KRW 10 billion. According to the market research institution UB
- Policy
- The copyrights of Valcyte, Alvesco, & Bonviva changed
- by Lee, Tak-Sun Jan 27, 2023 05:50am
- As the domestic owners of major drugs such as Valcyte, Alvesco, and Bonviva changed, they were newly reflected in the salary list. All three items were previously copyrighted by the Korean branch of a global pharmaceutical company, but now domestic pharmaceutical companies are the owners. In the case of Valcyte 440mg, pharmaceutical companies
- Company
- Will the 3 asthma biodrugs finally be reimbursed this year?
- by Eo, Yun-Ho Jan 27, 2023 05:50am
- Whether the 3 new biologics for asthma will be listed for insurance reimbursement in Korea is receiving attention. According to industry sources, treatments for severe asthma including GSK Korea’s Nucala (mepolizumab), Teva-Handok’s Cinqair (reslizumab), and AstraZeneca Korea’s Fasenra (benralizumab) are undergoing processes for reimbu
